Eric Gauthier

730 total citations
14 papers, 383 citations indexed

About

Eric Gauthier is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Eric Gauthier has authored 14 papers receiving a total of 383 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 8 papers in Oncology and 3 papers in Cancer Research. Recurrent topics in Eric Gauthier's work include Advanced Breast Cancer Therapies (9 papers), HER2/EGFR in Cancer Research (4 papers) and Cancer Treatment and Pharmacology (3 papers). Eric Gauthier is often cited by papers focused on Advanced Breast Cancer Therapies (9 papers), HER2/EGFR in Cancer Research (4 papers) and Cancer Treatment and Pharmacology (3 papers). Eric Gauthier collaborates with scholars based in United States, Canada and France. Eric Gauthier's co-authors include Jim Mortimer, D. Gauvreau, Isabel Fortier, François Courchesne, Véronique Dièras, Dongrui R. Lu, Anil A. Joy, Karen A. Gelmon, Hope S. Rugo and Miguel Martín and has published in prestigious journals such as Cancer Research, Annals of Oncology and Environmental Research.

In The Last Decade

Eric Gauthier

12 papers receiving 367 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Eric Gauthier United States	6	122	84	80	75	65	14	383
Yuting Jiang China	14	18 0.1×	52 0.6×	60 0.8×	89 1.2×	34 0.5×	28	584
Constanze Richter Germany	11	29 0.2×	66 0.8×	27 0.3×	85 1.1×	12 0.2×	15	404
Fernando Postalli Rodrigues Brazil	14	57 0.5×	33 0.4×	54 0.7×	82 1.1×	8 0.1×	19	676
U. von Recklinghausen Germany	9	36 0.3×	70 0.8×	20 0.3×	238 3.2×	15 0.2×	10	530
Vianey Rodríguez-Lara Mexico	15	13 0.1×	92 1.1×	126 1.6×	156 2.1×	24 0.4×	26	589
Jeffrey A. Dill United States	12	17 0.1×	41 0.5×	63 0.8×	136 1.8×	19 0.3×	24	479
Lingfang Feng China	17	29 0.2×	71 0.8×	28 0.3×	260 3.5×	22 0.3×	41	723
Lihong Ding China	17	213 1.7×	33 0.4×	38 0.5×	28 0.4×	12 0.2×	27	955
Hai Luo China	14	24 0.2×	23 0.3×	58 0.7×	68 0.9×	12 0.2×	37	531
T. Kiss Hungary	10	99 0.8×	26 0.3×	41 0.5×	55 0.7×	5 0.1×	16	426

Countries citing papers authored by Eric Gauthier

Since Specialization

Citations

This map shows the geographic impact of Eric Gauthier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Gauthier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Gauthier more than expected).

Fields of papers citing papers by Eric Gauthier

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric Gauthier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Gauthier. The network helps show where Eric Gauthier may publish in the future.

Co-authorship network of co-authors of Eric Gauthier

This figure shows the co-authorship network connecting the top 25 collaborators of Eric Gauthier. A scholar is included among the top collaborators of Eric Gauthier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric Gauthier. Eric Gauthier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Chalasani, Pavani, Betsy C. Wertheim, Peter Kabos, et al.. (2025). 305MO Phase II trial of TDM-1 and palbociclib in metastatic HER2 positive breast cancer. ESMO Open. 10. 104877–104877.

Rocque, Gabrielle B., Joanne L. Blum, Yan Ji, et al.. (2024). Real-world quality-of-life of patients with HR+/HER2− advanced breast cancer treated with palbociclib plus endocrine therapy: EORTC QLQ-C30 results from POLARIS. Breast Cancer Research and Treatment. 209(3). 613–627. 1 indexed citations

Pusztai, Lajos, Ekaterina Kalashnikova, Monica Mita, et al.. (2024). Abstract PS06-02: Circulating tumor DNA (ctDNA) monitoring of estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) high risk breast cancer during adjuvant endocrine therapy. Cancer Research. 84(9_Supplement). PS06–2. 5 indexed citations

Tripathy, Debu, Joanne L. Blum, Meghan Karuturi, et al.. (2023). 373P Impact of comorbidities on real-world (rw) clinical outcomes of patients (pts) with hormone receptor-positive/human epidermal growth factor 2-negative (HR+/HER2-) advanced breast cancer (ABC) treated with palbociclib and enrolled in POLARIS. Annals of Oncology. 34. S332–S332. 3 indexed citations

Tripathy, Debu, Joanne L. Blum, Bethany Sleckman, et al.. (2023). Abstract P3-01-03: Characterization of neutropenia in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) advanced breast cancer on palbociclib in a real-world setting: Results from POLARIS. Cancer Research. 83(5_Supplement). P3–1. 1 indexed citations

Tripathy, Debu, Gabrielle B. Rocque, Joanne L. Blum, et al.. (2022). 251P Real-world clinical outcomes of palbociclib plus endocrine therapy (ET) in hormone receptor–positive advanced breast cancer: Results from the POLARIS trial. Annals of Oncology. 33. S651–S652. 5 indexed citations

Rugo, Hope S., Richard S. Finn, Karen A. Gelmon, et al.. (2019). Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole: Analysis From PALOMA-2. Clinical Breast Cancer. 20(2). e173–e180. 24 indexed citations

Im, S-A., Norikazu Masuda, Y-H Im, et al.. (2017). Efficacy and safety of palbociclib plus endocrine therapy in women with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) in the Asia-Pacific region: Data from PALOMA-2 and -3. Annals of Oncology. 28. x27–x27. 2 indexed citations

Gauthier, Eric, Laureen Dartois, Jeffrey A. Tice, et al.. (2017). Abstract P2-06-05: Development and validation of a new non-parametric breast cancer risk assessment model on US and European screening populations. Cancer Research. 77(4_Supplement). P2–6.

10.

Dièras, Véronique, HS Rugo, Karen A. Gelmon, et al.. (2017). Abstract P4-22-07: Long-term safety of palbociclib in combination with endocrine therapy in treatment-naive and previously treated women with HR+ HER2– advanced breast cancer: A pooled analysis from randomized phase 2 and 3 studies. Cancer Research. 77(4_Supplement). P4–22. 1 indexed citations

11.

Finn, RS, Yuqiu Jiang, Hope S. Rugo, et al.. (2016). Biomarker analyses from the phase 3 PALOMA-2 trial of palbociclib (P) with letrozole (L) compared with placebo (PLB) plus L in postmenopausal women with ER + /HER2– advanced breast cancer (ABC). Annals of Oncology. 27. vi554–vi554. 46 indexed citations

12.

Wang‐Gillam, Andrea, Susanne M. Arnold, Ronald M. Bukowski, et al.. (2010). A phase I dose escalation study of TTI-237 in patients with advanced malignant solid tumors. Investigational New Drugs. 30(1). 266–272. 11 indexed citations

13.

Gauthier, Eric, et al.. (2001). Environmental Pesticide Exposure as a Risk Factor for Alzheimer's Disease: A Case-Control Study. Environmental Research. 86(1). 37–45. 72 indexed citations

14.

Gauthier, Eric, et al.. (2000). Aluminum Forms in Drinking Water and Risk of Alzheimer's Disease. Environmental Research. 84(3). 234–246. 212 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact